ET-2 Inhibitors

Endothelin-2 Activity Modulators are chemicals that indirectly influence the activity of Endothelin-2 (ET-2) by primarily targeting endothelin receptors or related signaling pathways. These modulators include a range of endothelin receptor antagonists that block the interaction of ET-2 with ET_A and/or ET_B receptors. The endothelin system, consisting of peptides (ET-1, ET-2, and ET-3) and their receptors (ET_A and ET_B), plays a critical role in regulating vascular tone, cell proliferation, and various physiological processes. Inhibitors like Bosentan, Ambrisentan, and Macitentan are significant for their ability to modulate the effects of ET-2, particularly in the context of cardiovascular health, hypertension, and other related conditions. The mechanism of action of these modulators is centered on blocking the ET_A and/or ET_B receptors. ET_A receptor antagonists, such as Ambrisentan, Atrasentan, and BQ-123, specifically inhibit the ET_A receptor, which is predominantly responsible for the vasoconstrictive and proliferative effects of ET-2. Dual antagonists like Bosentan and Macitentan block both ET_A and ET_B receptors, offering a broader modulation of ET-2's actions, particularly in pathological conditions like pulmonary arterial hypertension (PAH) and heart failure. These antagonists prevent ET-2 from exerting its effects, thereby reducing vasoconstriction, abnormal cell proliferation, and other detrimental consequences associated with excessive ET-2 activity.